Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies

Blood

Volumn 98, Issue 7, 2001, Pages 2220-2228

  Secchiero, Paola ^a,b,c,d   Gonelli, Arianna ^a,b,c,d   Celeghini, Claudio ^a,b,c,d   Mirandola, Prisco ^a,b,c,d   Guidotti, Lia ^a,b,c,d   Visani, Giuseppe ^a,b,c,d   Capitani, Silvano ^a,b,c,d   Zauli, Giorgio ^a,b,c,d  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 3; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL;

EID: 0035496908     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.7.2220     Document Type: Article

References (64)

1. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682.
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271: 12687-12690.
3. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 1995;85:3378-3404.
4. Baker SJ, Reddy EP. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene. 1996;12:1-9.
5. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol. 1998;28:973-982.
6. Snell V, Clodi K, Zhao S, et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol. 1997;99:618-624.
7. Clodi K, Wimmer D, Li Y, et al. Expression of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol. 2000;111:580-586.
8. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11:255-260.
9. De Maria R, Zeuner A, Eramo A, et al. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature. 1999;401:489-493.
10. Zamai L, Secchiero P, Pierpaoli S, et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood. 2000;95:3716-3724.
11. Song K, Chen Y, Goke R, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and ceil cycle progression. J Exp Med. 2000;191: 1095-1103.
12. Jo M, Kim T-H, Seol D-W, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000;6:564-567.
13. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 2001;7:383-385.
14. Sprick MR, Weigand MA, Rieser E, et al. FADD/MRT1 and caspase 8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000; 12:599-609.
15. Kischkel FC, Lawrence DA, Chuntharapai, Schow P, Kim J, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase 8 to death receptors 4 and 5. Immunity. 2000;12:611-620.
16. Walczak H, Krammer PH. The CD95 (Apo-1/Fas) and the TRAIL (Apo-2L) apoptosis systems. Exp Cell Res. 2000;256:58-66.
17. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326:1-16.
18. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992;6:3051-3064.
19. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
20. Maciejewski JP, Selleri C, Sato T, et al. Nitric oxide suppression of human hematopoiesis in vitro: contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin Invest. 1995;96:1085-1092.
21. Selleri C, Sato T, Raiola AM, Rotoli B, Young NS, Maciejewski JP. Induction of nitric oxide synthase is involved in the mechanism of Fas-mediated apoptosis in haemopoietic cells. Br J Haematol. 1997;99:481-489.
22. Shami PJ, Moore JO, Gockerman JP, Hathorn JW, Misukonis MA, Weinberg JB. Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells. Leuk Res. 1995;9:527-533.
23. Richardson DR, Neumannova V, Nagy E, Ponka P. The effect of redox-related species of nitrogen monoxide on transferrin and iron uptake and cellular proliferation of erythroleukemia (K562) cells. Blood. 1995;86:3211-3219.
24. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998;188:2375-2380.
25. Gibellini D, Bassini A, Re MC, et al. Stroma-derived factor 1 alpha induces a selective inhibition of human erythroid development via the functional upregulation of Fas/CD95 ligand. Br J Haematol. 2000;111:432-440.
26. Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K. An improved colorimetric assay for interleukin 2. J Immunol Methods. 1986;93:157-165.
27. Zauli G, Vitale M, Re MC, et al. In vitro exposure to human immunodeficiency virus type 1 induces apoptotic cell death of the factor-dependent TF-1 hematopoietic cell line. Blood. 1994;83:167-175.
28. Zamai L, Falcieri E, Gobbi P, et al. Anti-BrdUrd labeling of newly synthesized DNA in HL-60 cells triggered to apoptosis. Cytometry. 1996;25:324-332.
29. Webb JL. Effects of more than one inhibitor. Enzymes Metab Inhibitors. 1963;1:487-512.
30. Tetteroo PA, Massaro F, Mulder A, Schreuder van Gelder R, von dem Borne AE. Megacaryoblastic differentiation of proerythroblastic K562 cell-line cells. Leuk Res. 1984;8:197-206.
31. Leist M, Gantner F, Jilg S, Wendel A. Activation of the 55 kD TNF receptor in necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis and nitrite release. J Immunol. 1995; 154:1307-1316.
32. Geng Y-J, Hellstrand K, Wennmalm A, Hansson GK. Apoptotic death of human leukemic cells induced by vascular cells expressing nitric oxide synthase in response to γ-interferon and tumor necrosis factor-α. Cancer Res. 1996;56:866-874.
33. Heneka MT, Loschmann PA, Gleichmann M, et al. Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with TNF-α/lipopolysacharide. J Neurochem. 1998;71:88-94.
34. Binder C, Schultz M, Hiddemann W, Oellerich M. Caspase-activation and induction of inducible nitric oxide-synthase during TNF-α-triggered apoptosis. Anticancer Res. 1999;19:1715-1720.
35. Sheikh MS, Burns TF, Huang Y, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 1998;58:1593-1598.
36. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 1999;59:734-741.
37. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A. 2000;97:1754-1759.
38. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol. 2000;20:205-212.
39. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood. 2000;96:3900-3906.
40. Gong B, Almasan A. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res. 2000;60: 5754-5760.
41. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998; 17:1675-1687.
42. Hu W-H, Johnson H, Shu H-B. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kB and JNK activation and apoptosis through distinct pathways. J Biol Chem. 1999; 274:30603-30610.
43. Nunokawa Y, Oikawa S, Tanaka S. Human inducible nitric oxide synthase gene is transcriptionally regulated by nuclear factor-kB dependent mechanism. Biocem Biophys Res Commun. 1996;223: 347-352.
44. Chlichlia K, Peter ME, Rocha M, et al. Caspase activation is required for nitric oxide-mediated CD95 (APO-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells. Blood. 1998;91:4311-4320.
45. Williams MS, Noguchi S, Henkart PA, Osawa Y. Nitric oxide synthase plays a signaling role in TcR-triggered apoptotic death. J Immunol. 1998; 161:6526-6531.
46. Zhao H, Dugas N, Mathiot C, et al. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying antiapoptotic activity. Blood. 1998;92:1031-1043.
47. Salvucci O, Carsana M, Bersani I, Tragni G, Anichini A. Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res. 2001;61:318-326.
48. Dimmeler S, Haendeler J, Nehls M, Zeiher A. Suppression of apoptosis by nitric oxide via inhibition of ICE-like and CPP-32-like proteases. J Exp Med. 1995;185:601-607.
49. Wink D, Cook J, Kim S, et al. Superoxide modulates the oxidation and nitrosation of thiols by nitric oxide-derived reactive intermediates. J Biol Chem. 1997;272:11147-11151.
50. Brune B, von Knethen A, Sandau KB. Nitric oxide (NO): an effector of apoptosis. Cell Death Differ. 1999;6:969-975.
51. Ushmorov A, Ratter F, Lehmann V, Droge W, Schirrmacher V, Umansky V. Nitric oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome C release. Blood. 1999;93:2342-2352.
52. Susin SA, Lorenzo HK, Zamzami N, et al. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J Exp Med. 1999;189:381-393.
53. Keogh SA, Walczak H, Bouchier-Hayes L, Martin SJ. Failure of Bcl-2 to block cytochrome C redistribution during TRAIL-induced apoptosis. FEBS Lett. 2000;471:93-98.
54. Walczak H, Bouchon A, Stahl H, Krammer PH. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capability on Bcl-2- or Bcl-XL-overexpressing chemotherapy-resistant tumor cells. Cancer Res. 2000;60:3051-3057.
55. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia. 1999;13:1817-1824.
56. Seol DW, Billiar TR. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J Biol Chem. 1999;274:2072-2076.
57. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res. 2000; 6:335-346.
58. Thomas WD, Zhang XD, Franco AV, Nguyen T, Hersey P. TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria. J Immunol. 2000;165:5612-5620.
59. Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pacreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene. 2000;19:5477-5486.
60. Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El Deiry WS. The caspase 9 inhibitor z-LEHD-fmk protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2000;60:6259-6265.
61. Brenner MK. Hematological malignancies. FASEB J. 1997;11:640-648.
62. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-162.
63. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157-163.
64. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-327.